A new trading day began on Friday, with Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) stock price up 8.37% from the previous day of trading, before settling in for the closing price of $4.90. AMLX’s price has ranged from $1.58 to $19.95 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 2300.59% over the past five years. Meanwhile, its annual earnings per share averaged -623.81%. With a float of $41.21 million, this company’s outstanding shares have now reached $67.71 million.
Let’s look at the performance matrix of the company that is accounted for 384 employees. In terms of profitability, gross margin is 53.5%, operating margin of -51.85%, and the pretax margin is -54.35%.
Amylyx Pharmaceuticals Inc (AMLX) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Amylyx Pharmaceuticals Inc is 39.47%, while institutional ownership is 61.63%. The most recent insider transaction that took place on Sep 30 ’24, was worth 59,429. In this transaction Co-Chief Executive Officer of this company sold 18,589 shares at a rate of $3.20, taking the stock ownership to the 3,120,569 shares. Before that another transaction happened on Sep 30 ’24, when Company’s Co-Chief Executive Officer sold 18,589 for $3.20, making the entire transaction worth $59,414. This insider now owns 3,220,569 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Latest Financial update
In its latest quarterly report, released on 6/30/2024, the company reported earnings of 0.3 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.56 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -623.81% per share during the next fiscal year.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Here are Amylyx Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 4.66. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.45, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -1.73 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) saw its 5-day average volume 1.99 million, a negative change from its year-to-date volume of 2.05 million. As of the previous 9 days, the stock’s Stochastic %D was 80.80%. Additionally, its Average True Range was 0.43.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 95.28%, which indicates a significant increase from 92.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.86% in the past 14 days, which was higher than the 79.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.05, while its 200-day Moving Average is $5.12. Nevertheless, the first resistance level for the watch stands at $5.58 in the near term. At $5.86, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.22. If the price goes on to break the first support level at $4.95, it is likely to go to the next support level at $4.59. The third support level lies at $4.31 if the price breaches the second support level.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
With a market capitalization of 361.50 million, the company has a total of 68,006K Shares Outstanding. Currently, annual sales are 380,790 K while annual income is 49,270 K. The company’s previous quarter sales were 88,640 K while its latest quarter income was -118,790 K.
